List view / Grid view
11 November 2015 | By Victoria White
The US National Academy of Medicine (NAM) recently announced the election of Dr Vasant “Vas” Narasimhan as a member of the Academy.
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
19 October 2015 | By Victoria White
Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson's disease in a Phase I clinical trial...
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
8 October 2015 | By Victoria White
The analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
1 October 2015 | By Victoria White
Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis...
28 September 2015 | By Victoria White
The combination also demonstrated significant health-related quality of life improvements, including overall health, physical and social functioning...
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
17 September 2015 | By Victoria White
BioInject will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics...
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
2 September 2015 | By Victoria White
Heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the MHRA Early Access to Medicines Scheme...
28 August 2015 | By Victoria White
Novartis has renewed its pledge with the World Health Organisation (WHO) to work to end leprosy by extending its donation of multidrug therapy medicines...
25 August 2015 | By Victoria White
The FDA has approved a label expansion for Promacta to treat low blood platelet count in paediatric patients with chronic immune thrombocytopenic purpura...
21 August 2015 | By Victoria White
Novartis is to acquire all remaining rights to GSK's ofatumumab to develop treatments for MS and other autoimmune indications...
